At Oak HC/FT, we have the privilege to meet with many talented founders tackling hard problems. We get the most excited when we see a team that is leveraging their deep prior experiences and combining it with the current technology wave to reimagine how a category operates. We are in the early innings of a transformation of how the life sciences industry leverages new technologies to discover and design therapies. We believe that this trend will compound, and are optimistic that it will lead to an increase in promising new therapies reaching the clinic for validation - and eventually patients. However, if the development and validation efforts are not reimagined in the same way that discovery is being accelerated, we will encounter a major bottleneck. Dash Bio was founded to help address this exact issue, and we are proud to announce that we are leading their $30 million Series A. This brings the company's total financing to $47.5 million, with participation from existing investors Freestyle Capital and Swift Ventures.
Drug discovery has never moved faster. This is precisely why we are expanding our focus in the area and looking at investment opportunities along the value chain in life sciences. AI is accelerating how drugs are coming to market, and new modalities are reaching diseases we couldn't touch a decade ago. But discovering a promising molecule is only the beginning. Turning it into an approved medicine requires years of development work. This includes proving a drug is safe, understanding how it behaves in the body, and generating the evidence regulators and sponsors need to keep a program moving or know when to stop it. That work is still largely manual, priced by the hour, and built around timelines measured in months rather than days. The number of new drug candidates entering development keeps climbing, but the number of approvals has stalled, and the gap between what science can create and what actually reaches patients keeps widening.
Dash is addressing this bottleneck by starting with bioanalysis, the lab-based testing that measures a drug's safety and efficacy in preclinical and clinical samples. It is the piece of drug development every program depends on and the piece most in need of modernization. It’s where biology becomes data and thesis becomes evidence, required at every stage from the earliest preclinical work through Phase IV. It is also a natural foothold. Solving bioanalysis well builds the sample-tracking, method-validation and customer trust that needed to expand into the other lab-based bottlenecks slowing drug development down.
Through a combination of custom robotics and proprietary software, Dash has begun to productize assay workflows in a way that turns this legacy industry into something new. Walking through their 24,000-square-foot GLP-compliant lab in Boston gives you the immediate sense that this team is thinking about things differently. Whether it’s the 3D printer they use to quickly produce spare parts or new creations for their automation workflows, or the custom built LIMS software they run to ensure they can deliver pipette level sample tracking and a degree of transparency that customers have not yet experienced in this industry, the Dash team has taken every step of the bioanalysis process and transformed it in a way that gives them a structural advantage on both speed, cost and scalable quality.
Whereas legacy players return results in months with opaque pricing and minimal process transparency, Dash can return results in days with upfront pricing and sample-level reporting. Dash's vertically integrated, tech-first architecture sidesteps both limitations at once, and it shows up in the numbers. Since launching go-to-market efforts roughly nine months ago, Dash has signed more than 30 customers, including four top-25 global pharmaceutical companies, with more than $50 million in identified annual customer value already on the table.
All of this has been made possible by a team that has lived through these challenges intimately. CEO Dave Johnson spent more than nine years at Moderna, rising to Chief Data and AI Officer. At Moderna, he architected the automation and informatics infrastructure that allowed the company to scale from a few hundred people to over 5,000, as they participated in Project Warpspeed and developed a mRNA vaccine that scaled to over 3 billion doses annually within 2 years. Ander Tallet, co-founder and COO, was part of the Moderna team as well and is world-class in solving efficiency bottlenecks and building the foundations for scale. Dave and Ander are joined by Ely Porter as CSO, who co-founded Rootpath, a pioneer in developing cutting edge scientific solutions.
Drug development is a massive, structurally underserved market, and bioanalysis is just the entry point. We believe the same automation-first, transparently-priced model Dash is proving out today can extend across the many other lab-based services that sponsors rely on, giving Dash a credible path to becoming a much larger piece of drug development's infrastructure over time. We are proud to partner with Dave, Ander, Ely, and the entire Dash Bio team. It's time to run with Dash.
